Skip to main content

Advertisement

Table 1 Summary of demographics of cats participating in the intravenous allogeneic cryopreserved studies

From: Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies

Cat no. Group Description IRIS CKD stage and creatinine (mg/dl) Treatment
1 Pilot study 1 10 yr MC DSH IRIS CKD II; creatinine: 2.5 2 × 106 MSCs intravenously × 3 treatments
2 Pilot study 1 15 yr FS DSH IRIS CKD III; creatinine: 3.5 2 × 106 MSCs intravenously × 3 treatments
3 Pilot study 1 7 yr MC Siamese IRIS CKD III; creatinine: 4.3 2 × 106 MSCs intravenously × 3 treatments
4 Pilot study 1 12 yr MC DLH IRIS CKD II; creatinine: 2.4 2 × 106 MSCs intravenously × 3 treatments
5 Pilot study 1 15 yr MC DSH IRIS CKD II; creatinine: 2.3 2 × 106 MSCs intravenously × 3 treatments
6 Pilot study 1 15 yr FS Siamese IRIS CKD III; creatinine: 3.5 2 × 106 MSCs intravenously × 3 treatments
7 Pilot study 2 11 yr MC DSH IRIS CKD II; creatinine: 1.9 4 × 106 MSCs intravenously × 3 treatments
8 Pilot study 2 11 yr FS DSH IRIS CKD II; creatinine: 2.6 4 × 106 MSCs intravenously × 3 treatments
9 Pilot study 2 18 yr FS DSH IRIS CKD II; creatinine: 2.8 4 × 106 MSCs intravenously × 3 treatments
10 Pilot study 2 15 yr MC DSH IRIS CKD II; creatinine: 2.2 4 × 106 MSCs intravenously × 3 treatments
11 Pilot study 2 7 yr MC DSH IRIS CKD III; creatinine: 3.7 4 × 106 MSCs intravenously × 3 treatments
12 Pilot study 2 15 yr MC DSH IRIS CKD II; creatinine: 2.3 Iohexol GFR repeatability only
13 Pilot study 2 16 yr MC DSH IRIS CKD II; creatinine: 2.1 Iohexol GFR repeatability only
14 Pilot study 2 16 yr MC DSH IRIS CKD II; creatinine: 1.8 Iohexol GFR repeatability only
15 Pilot study 3 9 yr MC DSH IRIS CKD II; creatinine: 2.6 Enrolled but decompensated before treatment initiated
16 Pilot study 3 15 yr MC Siamese IRIS CKD II; creatinine: 2.4 4 × 106 MSCs intravenously × 2 treatments before recurrence of previous diabetes
17 Pilot study 3 13 yr MC Siamese IRIS CKD II; creatinine: 2.7 4 × 106 MSCs intravenously × 3 treatments
18 Pilot study 3 8 yr MC DSH IRIS CKD II; creatinine: 1.7 4 × 106 MSCs intravenously × 3 treatments
19 Pilot study 3 13 yr MC DSH IRIS CKD II; creatinine: 2.0 4 × 106 MSCs intravenously × 3 treatments
20 Pilot study 3 15 yr MC DLH IRIS CKD II; creatinine: 2.3 4 × 106 MSCs intravenously × 3 treatments
21 Pilot study 3 15 yr FS DSH IRIS CKD III; creatinine: 3.1 4 × 106 MSCs intravenously × 3 treatments
  1. Six cats were enrolled in pilot study 1 and received 2 × 106 cryopreserved adipose-derived mesenchymal stem cells (aMSCs) per infusion. In pilot study 2 eight cats were enrolled; five received 4 × 106 cryopreserved aMSCs per infusion, and three cats received only iohexol clearance studies. In pilot study 3, seven cats were enrolled; five cats received 4 × 106 cryopreserved aMSCs cultured from cryopreserved adipose per infusion; two cats developed unrelated medical conditions and were removed from the trial. CKD, chronic kidney disease; GFR, glomerular filtration rate. MC = male castrated, FS = female spayed, DSH = domestic shorthair, DLH = domestic long hair, IRIS = International Renal Interest Society.